A Review of Fixed Drug Eruption with a Special Focus on Generalized Bullous Fixed Drug Eruption.
Anderson HJ, Lee JB.
Medicina (Kaunas). 2021 Sep 1;57(9):925. doi: 10.3390/medicina57090925.
Severe cutaneous adverse reactions.
Hung SI, Mockenhaupt M, Blumenthal KG, Abe R, Ueta M, Ingen-Housz-Oro S, Phillips EJ, Chung WH.
Nat Rev Dis Primers. 2024 Apr 25;10(1):30. doi: 10.1038/s41572-024-00514-0.
Fixed Drug Eruptions: An Update, Emphasizing the Potentially Lethal Generalized Bullous Fixed Drug Eruption.
Patel S, John AM, Handler MZ, Schwartz RA.
Am J Clin Dermatol. 2020 Jun;21(3):393-399. doi: 10.1007/s40257-020-00505-3.
Drugs and the skin: A concise review of cutaneous adverse drug reactions.
Del Pozzo-Magaña BR, Liy-Wong C.
Br J Clin Pharmacol. 2024 Aug;90(8):1838-1855. doi: 10.1111/bcp.15490. Epub 2022 Aug 29.
[Exanthematic drug eruption].
Ziemer M, Livingstone E.
Pathologie (Heidelb). 2025 Mar;46(2):90-100. doi: 10.1007/s00292-025-01418-w. Epub 2025 Feb 18.
Bullous Drug Reactions.
Mockenhaupt M.
Acta Derm Venereol. 2020 Feb 12;100(5):adv00057. doi: 10.2340/00015555-3408.
Annular drug eruptions.
Wu WH, Chu CY.
Clin Dermatol. 2022 Sep-Oct;40(5):450-465. doi: 10.1016/j.clindermatol.2021.12.008. Epub 2021 Dec 31.
Cutaneous adverse drug eruption: the role of drug patch testing.
Thaiwat S, Rojanapanthu P.
Int J Dermatol. 2023 Jan;62(1):108-114. doi: 10.1111/ijd.16398. Epub 2022 Oct 27.
Drug-induced panniculitides.
Borroni G, Torti S, D'Ospina RM, Pezzini C.
G Ital Dermatol Venereol. 2014 Apr;149(2):263-70.
Drug allergy and autoimmune diseases.
Watanabe Y, Yamaguchi Y.
Allergol Int. 2022 Apr;71(2):179-184. doi: 10.1016/j.alit.2022.02.001. Epub 2022 Feb 24.
